Concert Pharmaceuticals, Inc. (Nasdaq: CNCE) to Ring The Nasdaq Stock Market Closing Bell
October 24 2016 - 10:00AM
What: Concert
Pharmaceuticals, Inc. (Nasdaq:CNCE), a clinical stage
biopharmaceutical company focused on applying its DCE
Platform® (deuterated chemical entity platform) to create
novel medicines designed to address unmet patient needs, will visit
the Nasdaq MarketSite in Times Square to mark the company’s 10th
anniversary.
In honor of the occasion, Dr. Roger Tung, Co-Founder,
President and CEO, will ring the Closing Bell.
Where: Nasdaq MarketSite – 4 Times Square
– 43rd & Broadway – Broadcast Studio
When: Tuesday, October 25, 2016 – 3:45
p.m. to 4:00 p.m. ET
Concert Pharmaceuticals Contact: Justine
Koenigsberg 781-674-5284 ir@concertpharma.com
Nasdaq MarketSite: Emily Pan (646)
441-5120 emily.pan@nasdaq.com
Feed Information: Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media: For multimedia features such
as exclusive content, photo postings, status updates and video of
bell ceremonies, please visit our Facebook
page: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page: http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page: http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page: http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page: http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Closing
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Close, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market close of your choice.
About Concert Concert
Pharmaceuticals is a clinical stage biopharmaceutical company
focused on applying its DCE Platform® (deuterated
chemical entity platform) to create novel medicines designed to
address unmet patient needs. The Company's approach starts with
approved drugs in which deuterium substitution has the potential to
enhance clinical safety, tolerability or efficacy. Concert has
a broad pipeline of innovative medicines targeting
pulmonary diseases, including cystic fibrosis, central nervous
systems (CNS) disorders, as well as autoimmune and inflammatory
diseases. For more information please
visit www.concertpharma.com.
About Nasdaq Nasdaq (Nasdaq:NDAQ) is a
leading provider of trading, clearing, exchange technology,
listing, information and public company services across six
continents. Through its diverse portfolio of solutions, Nasdaq
enables customers to plan, optimize and execute their business
vision with confidence, using proven technologies that provide
transparency and insight for navigating today's global capital
markets. As the creator of the world's first electronic stock
market, its technology powers more than 70 marketplaces in 50
countries, and 1 in 10 of the world's securities transactions.
Nasdaq is home to more than 3,700 listed companies with a market
value of approximately $9.3 trillion and nearly 18,000 corporate
clients. To learn more, visit: nasdaq.com/ambition or
business.nasdaq.com.
-NDAQA-
Concert Pharmaceuticals (NASDAQ:CNCE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Concert Pharmaceuticals (NASDAQ:CNCE)
Historical Stock Chart
From Sep 2023 to Sep 2024